Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Cash from Financing Activities (2016 - 2025)

Palisade Bio (PALI) has disclosed Cash from Financing Activities for 16 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 1968.33% to $3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.3 million, a 37.55% increase, with the full-year FY2024 number at $9.6 million, down 14.34% from a year prior.
  • Cash from Financing Activities was $3.4 million for Q3 2025 at Palisade Bio, up from $4000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $12.0 million in Q3 2022 to a low of -$258000.0 in Q1 2025.
  • A 5-year average of $2.5 million and a median of $1.6 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 5203.45% in 2023, then crashed 112.75% in 2025.
  • Palisade Bio's Cash from Financing Activities stood at $1.2 million in 2021, then skyrocketed by 48.78% to $1.7 million in 2022, then crashed by 107.82% to -$134000.0 in 2023, then surged by 3205.97% to $4.2 million in 2024, then fell by 19.2% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Cash from Financing Activities are $3.4 million (Q3 2025), $4000.0 (Q2 2025), and -$258000.0 (Q1 2025).